
Opinion|Videos|December 16, 2024
Demographics and Baseline Characteristics Across Spesolimab Dose Groups
Key Takeaways
Panelists discuss how the Effisayil 2 trial included diverse patient demographics across different spesolimab dose groups, with baseline characteristics such as age, disease severity, and history of GPP flares influencing the treatment outcomes and safety data.
Advertisement
Episodes in this series

Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
New Consensus Defines Remission, Disease Activity in Atopic Dermatitis
2
Real-World Study Finds Experienced Dermatologists Outperform AI in Skin Cancer Diagnosis
3
Zasocitinib Shows High Skin Clearance at Hard-to-Treat Psoriasis Sites
4
Beyond Retinol: Evaluating the Stability, Safety, and Gene-Expression Profile of Bakuchiol Ferulate
5












